Ziconotide for treatment of severe chronic pain

Pharmacological management of severe chronic pain is difficult to achieve with currently available analgesic drugs, and remains a large unmet therapeutic need. The synthetic peptide ziconotide has been approved by the US Food and Drug Administration and the European Medicines Agency for intrathecal treatment of patients with severe chronic pain that is refractory to other treatment modalities. Ziconotide is the first member in the new drug class of selective N-type voltage-sensitive calcium-channel blockers. The ziconotide-induced blockade of N-type calcium channels in the spinal cord inhibits release of pain-relevant neurotransmitters from central terminals of primary afferent neurons. By this mechanism, ziconotide can effectively reduce pain. However, ziconotide has a narrow therapeutic window because of substantial CNS side-effects, and thus treatment with ziconotide is appropriate for only a small subset of patients with severe chronic pain. We provide an overview of the benefits and limitations of intrathecal ziconotide treatment and review potential future developments in this new drug class.

[1]  David John Adams,et al.  ω-Conotoxin inhibition of excitatory synaptic transmission evoked by dorsal root stimulation in rat superficial dorsal horn , 2008, Neuropharmacology.

[2]  Zhong-Ping Feng,et al.  Scaffold-based design and synthesis of potent N-type calcium channel blockers. , 2009, Bioorganic & medicinal chemistry letters.

[3]  L. Webster,et al.  A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. , 2006, Journal of pain and symptom management.

[4]  M. Wallace.  Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain , 2006, Expert review of neurotherapeutics.

[5]  C. Woolf,et al.  Can we conquer pain? , 2002, Nature Neuroscience.

[6]  J. McGivern.  Targeting N-type and T-type calcium channels for the treatment of pain. , 2006, Drug discovery today.

[7]  B. Olivera,et al.  Conus Peptides: Biodiversity-based Discovery and Exogenomics* , 2006, Journal of Biological Chemistry.

[8]  W R Gray,et al.  Peptide neurotoxins from fish-hunting cone snails. , 1985, Science.

[9]  H. Koganei,et al.  Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. , 2009, Biological & pharmaceutical bulletin.

[10]  J. Trimmer,et al.  Localization and targeting of voltage-dependent ion channels in mammalian central neurons. , 2008, Physiological reviews.

[11]  Christine M. Cheng,et al.  Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain , 2006, The Annals of pharmacotherapy.

[12]  S. Hassenbusch,et al.  Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel , 2007, Neuromodulation : journal of the International Neuromodulation Society.

[13]  H. Takimizu,et al.  L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models. , 2002, Bioorganic & medicinal chemistry letters.

[14]  R. Dworkin,et al.  Treatment of neuropathic pain: an overview of recent guidelines. , 2009, The American journal of medicine.

[15]  G. Geisslinger,et al.  No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing , 2009, Trends in Neurosciences.

[16]  R. Luther,et al.  Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. , 1998, Toxicon : official journal of the International Society on Toxinology.

[17]  P. Staats,et al.  Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. , 2008, Pain medicine.

[18]  Miljanich Gp,et al.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. , 2004, Current medicinal chemistry.

[19]  M. Byas-Smith,et al.  Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[20]  A. Takahara,et al.  Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity. , 2006, Bioorganic & medicinal chemistry.

[21]  C. Woolf,et al.  Central sensitization and LTP: do pain and memory share similar mechanisms? , 2003, Trends in Neurosciences.

[22]  L. Webster,et al.  Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. , 2008, Pain medicine.

[23]  R. Luther,et al.  Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. , 1997, Journal of cardiovascular pharmacology.

[24]  L. Sorkin,et al.  Upregulation of Dorsal Root Ganglion α2δ Calcium Channel Subunit and Its Correlation with Allodynia in Spinal Nerve-Injured Rats , 2001, The Journal of Neuroscience.

[25]  S. Hassenbusch,et al.  Future Directions for Intrathecal Pain Management: A Review and Update From the Interdisciplinary Polyanalgesic Consensus Conference 2007 , 2008, Neuromodulation : journal of the International Neuromodulation Society.

[26]  A. Dolphin,et al.  Identification of the (cid:1) 2 - (cid:2) -1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin , 2006 .

[27]  A. Takahara,et al.  Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. , 2009, Current topics in medicinal chemistry.

[28]  J. Ramachandran,et al.  Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. , 1995, Annual review of pharmacology and toxicology.

[29]  C. Taylor.  Mechanisms of analgesia by gabapentin and pregabalin – Calcium channel α2-δ [Cavα2-δ] ligands , 2009, Pain.

[30]  M. Drass,et al.  Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients , 2003, Journal of clinical pharmacology.

[31]  L. Webster,et al.  Intrathecal Ziconotide for Complex Regional Pain Syndrome: Seven Case Reports , 2009, Pain practice : the official journal of World Institute of Pain.

[32]  L. Nádasdi,et al.  Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion , 2000, Peptides.

[33]  C. Zhang,et al.  Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence. , 2008, European journal of pharmacology.

[34]  A. Burton,et al.  Intrathecal Ziconotide for Neuropathic Pain: A Review , 2009, Pain practice : the official journal of World Institute of Pain.

[35]  D. Wermeling,et al.  Ziconotide, an Intrathecally Administered N‐Type Calcium Channel Antagonist for the Treatment of Chronic Pain , 2005, Pharmacotherapy.

[36]  M. Byas-Smith,et al.  Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. , 2004, JAMA.

[37]  T. Yaksh,et al.  Ziconotide , 2006 .

[38]  H. Uneyama,et al.  Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. , 2006, Bioorganic & medicinal chemistry letters.

[39]  A. J. Castiglioni,et al.  Cell-Specific Alternative Splicing Increases Calcium Channel Current Density in the Pain Pathway , 2004, Neuron.

[40]  James C. Thompson,et al.  Treatment challenges and complications with ziconotide monotherapy in established pump patients. , 2006, Pain physician.

[41]  T. Tanabe,et al.  Plastic Change of N-type Ca Channel Expression after Preconditioning Is Responsible for Prostaglandin E2-induced Long-lasting Allodynia , 2003, Anesthesiology.

[42]  M. R. Feng,et al.  Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties. , 1999, Journal of medicinal chemistry.

[43]  C. Altier,et al.  Targeting Ca2+ channels to treat pain: T-type versus N-type. , 2004, Trends in pharmacological sciences.

[44]  Aaron M. Beedle,et al.  Determinants of Inhibition of Transiently Expressed Voltage-gated Calcium Channels by ω-Conotoxins GVIA and MVIIA* , 2003, Journal of Biological Chemistry.

[45]  Yongxiang Wang,et al.  Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats , 2000, PAIN®.

[46]  B. Olivera,et al.  Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. , 2007, Molecular interventions.

[47]  J. Heavner,et al.  Ziconotide: an update and review. , 2008, Expert opinion on pharmacotherapy.

[48]  H. Rhim,et al.  Impaired long‐term memory and long‐term potentiation in N‐type Ca2+ channel‐deficient mice , 2007, Genes, brain, and behavior.

[49]  H. Takimizu,et al.  Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. , 2001, Bioorganic & medicinal chemistry letters.

[50]  Howard S. Smith,et al.  Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain , 2009, Therapeutics and clinical risk management.

[51]  M. Panda,et al.  Update in Pain Medicine , 2008, Journal of General Internal Medicine.

[52]  K. Kroenke,et al.  Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. , 2009, General hospital psychiatry.

[53]  L. Webster,et al.  Long-term intrathecal ziconotide for chronic pain: an open-label study. , 2009, Journal of pain and symptom management.

[54]  G. Stix.  A toxin against pain. , 2005, Scientific American.

[55]  W. Wayt Gibbs,et al.  Obesity: an overblown epidemic? , 2005, Scientific American.

[56]  Miljanich Gp,et al.  Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. , 2004 .

[57]  B. Collett,et al.  Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.

[58]  T. Snutch.  Targeting chronic and neuropathic pain: The N-type calcium channel comes of age , 2005, NeuroRX.

[59]  J. Ramachandran,et al.  Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC) , 1994, Brain Research.

[60]  L. Kapural,et al.  An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide. , 2006, Journal of pain and symptom management.

[61]  M. Wallace,et al.  Intrathecal Ziconotide for Severe Chronic Pain: Safety and Tolerability Results of an Open-Label, Long-Term Trial , 2008, Anesthesia and analgesia.

[62]  J. McIntosh,et al.  Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. , 1987, Biochemistry.

[63]  U. Klotz.  Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review. , 2006, International journal of clinical pharmacology and therapeutics.

[64]  T. Yaksh,et al.  Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury , 2002, Experimental Brain Research.